Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026

Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia™ JUPITER, FL, March 02, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that management will participate in the BIO Investment and Growth Summit 2026, hosted by the Biotechnology Innovation Organization (BIO ...